BetterLife Pharma Inc (OTCMKTS:PVOTF) expects to publish results of the third-party study of the drug – Interferon Alpha-2b in the journal Frontiers of Immunology this Friday. The company has examined the effectiveness of Interferon Alpha-2b on seventy-seven Wuhan based patients infected with moderate to severe coronavirus during January 16 and February 20, 2020. According to the study, the drug can effectively clear the coronavirus from the airways of affected patients.
An unexplored and uncontrolled study is conducted on seventy-seven patients in Wuhan by administering arbidol (200 mg t.i.d.) or nebulized IFN-α2b (5 mU b.i.d.) or a combination of both. In the trial, temperature, serum cytokine levels, blood chemistry, cell counts, and blood oxygen saturation levels are recorded. Interferon Alpha-2b has effectively reduced coronavirus duration either with or without arbidol in the upper respiratory tract. Further investigation is required on IFN-α2b to treat COVID-19.
Should give priority for clinical trials of Interferon Alpha-2b
The study is featured in the Canadian national newspaper – Globe and Mail in its May 13, edition under the article title ‘Interferon emerges as a potential treatment for COVID-19’. A researcher at Toronto University Health Network – Dr. Eleanor Fish said the awareness about this drug to treat coronavirus is slow and should give priority for the clinical trials on a large scale.
Interferons to treat coronavirus infections
According to Fish, interferons provide the first line of defense against all the viruses. However, viruses like coronavirus have evolved to block the response of interferon. It necessitates the need for interferons to treat coronavirus infections.
The new drug of BetterLife Pharma overrides the inhibitory effects of COVID-19. Fish said that instead of developing a virus-specific antiviral every time, it is better to consider interferons for the treatment of viruses like coronavirus.
Interferons have already received the nod to